240 related articles for article (PubMed ID: 24405639)
21. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia.
Guo SX; Taki T; Ohnishi H; Piao HY; Tabuchi K; Bessho F; Hanada R; Yanagisawa M; Hayashi Y
Leuk Res; 2000 Jan; 24(1):39-46. PubMed ID: 10634644
[TBL] [Abstract][Full Text] [Related]
23. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
[TBL] [Abstract][Full Text] [Related]
24. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
Inoue K; Sugiyama H; Ogawa H; Nakagawa M; Yamagami T; Miwa H; Kita K; Hiraoka A; Masaoka T; Nasu K
Blood; 1994 Nov; 84(9):3071-9. PubMed ID: 7949179
[TBL] [Abstract][Full Text] [Related]
25. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
26. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
27. [Detection of WT1 expression in bone marrow of acute leukemia patients with real-time quantitative RT-PCR].
Gu WY; Chen ZX; Cao XS; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):728-31. PubMed ID: 15730716
[TBL] [Abstract][Full Text] [Related]
28. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry.
Trka J; Kalinová M; Hrusák O; Zuna J; Krejcí O; Madzo J; Sedlácek P; Vávra V; Michalová K; Jarosová M; Starý J;
Leukemia; 2002 Jul; 16(7):1381-9. PubMed ID: 12094264
[TBL] [Abstract][Full Text] [Related]
29. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
[TBL] [Abstract][Full Text] [Related]
30. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
31. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
Willasch AM; Gruhn B; Coliva T; Kalinova M; Schneider G; Kreyenberg H; Steinbach D; Weber G; Hollink IH; Zwaan CM; Biondi A; van der Velden VH; Reinhardt D; Cazzaniga G; Bader P; Trka J;
Leukemia; 2009 Aug; 23(8):1472-9. PubMed ID: 19322206
[TBL] [Abstract][Full Text] [Related]
32. Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia.
Zhang ZH; Zhang W; Zhou JD; Zhang TJ; Ma JC; Xu ZJ; Lian XY; Wu DH; Wen XM; Deng ZQ; Lin J; Qian J
Mol Carcinog; 2018 Jun; 57(6):735-744. PubMed ID: 29457658
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Nguyen C; Liang G; Nguyen TT; Tsao-Wei D; Groshen S; Lübbert M; Zhou JH; Benedict WF; Jones PA
J Natl Cancer Inst; 2001 Oct; 93(19):1465-72. PubMed ID: 11584062
[TBL] [Abstract][Full Text] [Related]
34. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
[TBL] [Abstract][Full Text] [Related]
35. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
Rodrigues PC; Oliveira SN; Viana MB; Matsuda EI; Nowill AE; Brandalise SR; Yunes JA
Pediatr Blood Cancer; 2007 Aug; 49(2):133-8. PubMed ID: 16883592
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients.
Mossallam GI; Abdel Hamid TM; Mahmoud HK
Hematology; 2013 Mar; 18(2):69-73. PubMed ID: 23394625
[TBL] [Abstract][Full Text] [Related]
38. Expression of Wilms tumor gene (WT1) in children with acute leukemia.
Im HJ; Kong G; Lee H
Pediatr Hematol Oncol; 1999; 16(2):109-18. PubMed ID: 10100271
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic inactivation of the MIR129-2 in hematological malignancies.
Wong KY; Yim RL; Kwong YL; Leung CY; Hui PK; Cheung F; Liang R; Jin DY; Chim CS
J Hematol Oncol; 2013 Feb; 6():16. PubMed ID: 23406679
[TBL] [Abstract][Full Text] [Related]
40. [Methylation status of IEX-1 gene promotor CpG island in malignant hematopoietic cell lines].
Li XY; Shen JZ; Shen SF; Fu HY; Zhou HR; Wu DS; Zhang YY; Zheng YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):473-6. PubMed ID: 21518511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
